Christopher Pierce compensation by year
Prelude Therapeutics Summary Compensation Table · the one fiscal year held| Component | FY2020 |
|---|---|
| Salary | $204,029 |
| Bonus | $0 |
| Stock awards | $0 |
| Option awards | $3,594,492 |
| Non-equity incentive | $132,344 |
| Pension and deferred compensation | $0 |
| All other | $0 |
| Total | $3,930,865 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Prelude Therapeutics Inc DEF 14A filed April 29, 2021, accession 0001193125-21-140361, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Prelude Therapeutics Inc filed document, accession 0001193125-21-140361. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2021.
Equity holdings
unvested awards at FY2020 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 324,224 | — | $12.85 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Prelude Therapeutics Inc's FY2020 proxy; value at the fiscal year-end close, as the company printed it.
Prelude Therapeutics’s named executive officers, FY2020
as the company reported each| Named executive officer | Role | FY2020 total |
|---|---|---|
| Krishna Vaddi | Chief Executive Officer | $11,632,464 |
| Christopher Pierce · this page | Executive Vice President and Chief of Business Operations | $3,930,865 |
| Deborah Morosini | Executive Vice President and Chief of Clinical Affairs | $3,921,302 |
| Peggy Scherle | Chief Scientific Officer | $2,690,241 |
| Andrew Combs | EVP and Head of Chemistry | $2,016,063 |
| Brian Piper | Former Chief Financial Officer | $1,961,340 |
The full Prelude Therapeutics compensation record
free company briefThis page is one person within Prelude Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Prelude Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.